UTMD

Business Context and Reporting Period

Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2011
Business Overview: UTMD manufactures and markets specialty medical devices. The quarter was defined by the strategic acquisition of Femcare Holdings Ltd (Femcare), a UK-based company known for the Filshie Clip female surgical contraception device, on March 18, 2011.

Key Financial Metrics

Note: All figures in thousands except per share data. Debt figures include current and long-term notes payable.

Material Changes vs. Prior Period

• Acquisition Impact: The purchase of Femcare for approximately $41 million fundamentally altered the balance sheet. Total assets nearly doubled from $41.2 million to $81.9 million, driven by $38.6 million in identifiable intangible assets and $9.1 million in goodwill.
• Revenue Growth: Net sales increased 5.5% to $6.79 million. Excluding Femcare's 10-day contribution ($491k), organic sales were down 2% due to a 4% decline in domestic sales, partially offset by a 25% increase in international sales.
• Profitability: Net income decreased 12.5% to $1.34 million. This decline was primarily due to $259k in one-time acquisition-related expenses and $46k in new interest expense from acquisition financing.
• Liquidity and Leverage: To finance the acquisition, UTMD incurred $26.9 million in new debt (loans from JPMorgan Chase in the U.S. and U.K.). Consequently, the debt-to-asset ratio surged from 8% to 53%, and the current ratio dropped from 13.2 to 1.6.
• Working Capital: Working capital decreased by $16.6 million to $6.6 million, reflecting the cash outflow for the acquisition and the assumption of Femcare's liabilities.

Guidance, Outlook, and Risks

• Management Outlook: Management expects the acquisition to be accretive to financial performance in 2011 and beyond. The company targets full-year 2011 EPS of approximately $1.95, representing an 18% increase over 2010.
• Margin Projections: Combined Gross Profit Margin is projected to reach ~60% for the remainder of 2011. Operating Profit Margin is expected to settle in the 28-29% range due to amortization of acquired intangible assets.
• Debt Servicing: The company plans to repay the $26.9 million debt over five years using operating profits and cash flow from intangible asset amortization. Interest expense is projected to reduce Earnings Before Tax by approximately $1.09 million in the first year.
• Risk Factors:
  • Regulatory: Risks associated with U.S. healthcare reform (excise taxes, administrative costs) and FDA regulatory delays.
  • Market: Reliance on Group Purchasing Organizations (GPOs) which may commoditize products; foreign exchange fluctuations affecting international revenue.
  • Operational: Integration risks of the Femcare acquisition and reliance on third-party distributors for international sales.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline for finalizing the purchase price allocation and potential adjustments to the $3.2 million escrow.
• Debt Covenants: Monitor compliance with loan covenants, specifically the Leverage Ratio (max 2.75:1) and Interest Coverage Ratio (min 1.15:1).
• Amortization Impact: Assess the long-term impact of amortizing $38.5 million in intangible assets over 15 years on future operating margins.
• Organic Growth: Distinguish between Femcare-driven revenue growth and organic performance, noting the 4% decline in domestic sales excluding the acquisition.
• Foreign Exchange: Evaluate exposure to GBP and EUR fluctuations given the new international footprint and debt obligations.